Left Atrial Functional Remodeling in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan. 2023

Michele Correale, and Michele Magnesa, and Pietro Mazzeo, and Martino Fortunato, and Lucia Tricarico, and Alessandra Leopizzi, and Adriana Mallardi, and Raffaele Mennella, and Francesca Croella, and Massimo Iacoviello, and Matteo Di Biase, and Natale Daniele Brunetti
Cardiology Unit, Cardio-Thoracic Department, Policlinico Riuniti University Hospital, Viale Luigi Pinto 1, 71100 Foggia, Italy.

(1) Background: Previous studies showed left ventricular (LV) and left atrial (LA) improvement and reverse remodeling after therapy with Sacubitril/Valsartan (S/V) in patients affected by heart failure with reduced ejection fraction (HFrEF). Therefore, we sought to investigate predictors of LA structural and functional reverse remodeling (LARR) in this setting of patients after therapy with S/V, focusing on left atrial strain parameters, such as peak atrial longitudinal strain (PALS). (2) Methods: Patients with HFrEF underwent clinical and echocardiographic evaluation at baseline and after six months of therapy with S/V. Measures of LA structure (LA volume index, LAVi) and function (LA emptying fraction (LAEF), PALS, LA conduit strain and peak atrial contraction strain (PACS) were also analyzed. Patients were divided in two groups, those with a LARR (relative reduction in LAVi > 15%, LARR+) and those without (LARR-). (3) Results: A total of 47 consecutive patients (66 ± 8 years, 85% male, mean LVEF 28 ± 6%) were enrolled in the study and followed up. A significant increase of LAEF (46 ± 13 vs. 37 ± 11%, p < 0.001) and a significant reduction of LAVi (42 ± 15 vs. 45 ± 15 mL/m2, p = 0.008) were found after 6 months of S/V therapy; 47% of the population showed LA reverse remodeling. LA strain parameters, PALS (19 ± 8 vs. 15 ± 7 %, p < 0.001) and LA conduit (-9.7 ± 5.2% vs. -7.6 ± 4.1%, p = 0.007) significantly improved after 6 months of S/V therapy. At multivariable stepwise regression analysis, changes in LV End Diastolic Volume (LVEDV) and PALS were significantly proportional to changes in LAVi values. (4) Conclusions: Six months of treatment with S/V in patients with HFrEF was associated with an improvement in LA functional reverse remodeling in a real-world scenario. LARR was not significantly correlated to baseline echocardiographic variables, but was proportional to changes in LV volumes and LA strain parameters. Finally, after S/V therapy, a strict connection between LA and LV reverse remodeling and between LA anatomical and functional reverse remodeling seems to be outlined.

UI MeSH Term Description Entries

Related Publications

Michele Correale, and Michele Magnesa, and Pietro Mazzeo, and Martino Fortunato, and Lucia Tricarico, and Alessandra Leopizzi, and Adriana Mallardi, and Raffaele Mennella, and Francesca Croella, and Massimo Iacoviello, and Matteo Di Biase, and Natale Daniele Brunetti
January 2023, Journal of clinical medicine,
Michele Correale, and Michele Magnesa, and Pietro Mazzeo, and Martino Fortunato, and Lucia Tricarico, and Alessandra Leopizzi, and Adriana Mallardi, and Raffaele Mennella, and Francesca Croella, and Massimo Iacoviello, and Matteo Di Biase, and Natale Daniele Brunetti
January 2018, Journal of cardiovascular pharmacology and therapeutics,
Michele Correale, and Michele Magnesa, and Pietro Mazzeo, and Martino Fortunato, and Lucia Tricarico, and Alessandra Leopizzi, and Adriana Mallardi, and Raffaele Mennella, and Francesca Croella, and Massimo Iacoviello, and Matteo Di Biase, and Natale Daniele Brunetti
December 2016, Australian prescriber,
Michele Correale, and Michele Magnesa, and Pietro Mazzeo, and Martino Fortunato, and Lucia Tricarico, and Alessandra Leopizzi, and Adriana Mallardi, and Raffaele Mennella, and Francesca Croella, and Massimo Iacoviello, and Matteo Di Biase, and Natale Daniele Brunetti
June 2019, Journal of the American College of Cardiology,
Michele Correale, and Michele Magnesa, and Pietro Mazzeo, and Martino Fortunato, and Lucia Tricarico, and Alessandra Leopizzi, and Adriana Mallardi, and Raffaele Mennella, and Francesca Croella, and Massimo Iacoviello, and Matteo Di Biase, and Natale Daniele Brunetti
February 2017, Prescrire international,
Michele Correale, and Michele Magnesa, and Pietro Mazzeo, and Martino Fortunato, and Lucia Tricarico, and Alessandra Leopizzi, and Adriana Mallardi, and Raffaele Mennella, and Francesca Croella, and Massimo Iacoviello, and Matteo Di Biase, and Natale Daniele Brunetti
August 2021, Die Pharmazie,
Michele Correale, and Michele Magnesa, and Pietro Mazzeo, and Martino Fortunato, and Lucia Tricarico, and Alessandra Leopizzi, and Adriana Mallardi, and Raffaele Mennella, and Francesca Croella, and Massimo Iacoviello, and Matteo Di Biase, and Natale Daniele Brunetti
May 2017, Annals of internal medicine,
Michele Correale, and Michele Magnesa, and Pietro Mazzeo, and Martino Fortunato, and Lucia Tricarico, and Alessandra Leopizzi, and Adriana Mallardi, and Raffaele Mennella, and Francesca Croella, and Massimo Iacoviello, and Matteo Di Biase, and Natale Daniele Brunetti
May 2017, Annals of internal medicine,
Michele Correale, and Michele Magnesa, and Pietro Mazzeo, and Martino Fortunato, and Lucia Tricarico, and Alessandra Leopizzi, and Adriana Mallardi, and Raffaele Mennella, and Francesca Croella, and Massimo Iacoviello, and Matteo Di Biase, and Natale Daniele Brunetti
May 2017, Annals of internal medicine,
Michele Correale, and Michele Magnesa, and Pietro Mazzeo, and Martino Fortunato, and Lucia Tricarico, and Alessandra Leopizzi, and Adriana Mallardi, and Raffaele Mennella, and Francesca Croella, and Massimo Iacoviello, and Matteo Di Biase, and Natale Daniele Brunetti
May 2017, Annals of internal medicine,
Copied contents to your clipboard!